Abstract: A method of dosing a psychedelic that avoids the side effects of hallucinations and perceptual disturbances by administering the psychedelic to an individual in a titrating dosing regimen and reducing side effects of hallucinations and perceptual disturbances. A kit for administering a titrating dosing regimen of a psychedelic, including a pharmaceutically effective amount of the psychedelic in dosage forms separated in packaging according to dose and time of administration in a titrating dosing regimen, and instructions for use. A method of treating an individual with psychedelics, by administering the psychedelic to the individual having a condition or disease in a titrating dosing regimen and reducing side effects of hallucinations and perceptual disturbances during treatment.

Abstract: A composition for use in psychotherapeutic or medical treatment of an R(?) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.

Abstract: A method of treating movement disorders, by administering an effective amount of a psychedelic to an individual having a movement disorder, and treating the movement disorder.

Abstract: A composition for use in psychotherapeutic or medical treatment of an R(?) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.

Abstract: A composition for use in psychotherapeutic or medical treatment of an R(?) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.

Abstract: A method of analyzing a patient's mental state, by automatically processing, integrating, and analyzing text-based and audio-based sources from the patient and clinical staff, and generating real-time outcomes and predictions. A system for processing, analyzing, and managing a patient's input including a data pool, model HUB, search service, topic modeling service, mental health related prediction service, and analytics all in electronic communication. A method of analyzing a patient, by processing, analyzing, and managing a patient's and clinical staff's text and audio input, and informing and augmenting diagnostic and prognostic processes, identifying improvement and deterioration of a patient's mental state, and identifying adverse events in psychotherapy, counseling, and other mental health management activities. A system for processing, analyzing, and managing clinical and diagnostic texts, and audio transcripts.

Abstract: A system for monitoring patients during a consciousness-altering therapeutic treatment session including a data collection module in electronic communication with network servers for storage of data on non-transitory computer readable media for monitoring a patient's well-being during and after the treatment session. A method of using the system in treating a patient, by continuously, continually, or at the healthcare professionals discretion monitoring the well-being of the patient during a consciousness-altering therapeutic treatment session through one or more wearable devices and a patient mobile device in electronic communication with a facilitator mobile device, and continuously monitoring the well-being of the patient after the treatment session with the wearable device.

Abstract: A method of treating obesity, by administering an effective amount of a composition chosen from the group consisting of 18-methoxycoronaridine (18-MC), salts thereof, tartrates thereof, solvates thereof, isomers thereof, analogs thereof, homologues thereof, and deuterated forms thereof to an individual and treating obesity. A method of treating binge eating, by administering an effective amount of the composition to an individual and treating binge eating. A method of treating behavioral addictions, by administering an effective amount of the composition to an individual and treating the behavioral addiction.

Abstract: A method of data collection of stool data via a mobile device operable to enable monitoring of gastrointestinal function. A related method of long-term monitoring of patient gastrointestinal function, using one or more signal processing tools (e.g. machine learning algorithms) for automatically interpreting patient stool data, including real-time patient-assessments, in order to detect an adverse clinical event from patient stool data. A system for facilitating real-time monitoring the gastrointestinal function, the system comprising: a camera on a mobile device, a user interface that facilitates self-monitoring of stool characteristics, so as to create health-monitoring data; mobile device storage, server storage, and remote storage (with at least one communication link between them) for storing some or all of the health-monitoring data; and a processor for interpreting such health-monitoring data for clinical or other health-monitoring application.

Abstract: Disclosed in the present disclosure is a method, system and apparatus for prediction, estimation and prevention of occurrence of agitation episode in a subject predisposed to agitation. The method comprises receiving, from a first monitoring device attached to a subject, physiological data of sympathetic nervous system activity in the subject and activity data of the subject; receiving, from a computing device, a plurality of indications associated with a plurality of agitation episodes of the subject; analyzing, using at least one machine learning model, the physiological data, the activity data, and the plurality of indications to determine a probability of an occurrence of an agitation episode of the subject; and sending a signal to a second monitoring device to notify the second monitoring device of the probability of the occurrence of the agitation episode of the subject such that treatment can be provided to the subject to decrease sympathetic nervous system activity in the subject.

Abstract: A composition for treating an individual while reducing acute effects, including effective amounts of a psychedelic drug and a duration shortening agent. A method of treating an individual with a psychedelic drug and reducing or eliminating its acute duration of action, by administering a psychedelic drug to the individual, administering a duration shortening agent to the individual, and shortening and/or reducing and/or eliminating the acute effects of the psychedelic drug. A method of stopping the acute duration of action of a psychedelic drug in an individual, by administering a duration shortening agent to the individual after the individual has taken a psychedelic drug and stopping the acute effects of the psychedelic drug. A method of stopping psychosis due to psychedelic administration, by administering a duration shortening agent to the individual after the individual has taken a psychedelic drug, and stopping psychosis caused by the psychedelic drug.

Abstract: A method of treating pain, by administering an effective amount of a psychedelic to an individual and treating pain in the individual. A method of treating a pain syndrome, by administering an effective amount of a psychedelic to an individual, and providing a central effect, an effect on depression, and an inflammatory effect.

Abstract: A method of treating movement disorders, by administering an effective amount of a psychedelic to an individual having a movement disorder, and treating the movement disorder.

Abstract: A composition for use in psychotherapeutic or medical treatment of an R(?) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.

Abstract: A method of treating pain, by administering an effective amount of a psychedelic to an individual and treating pain in the individual.

Abstract: In some embodiments, a method includes receiving first physiological data of sympathetic nervous system activity and establishing a baseline value of at least one physiological parameter by training at least one machine learning model using the first physiological data. The method further includes receiving, from a first monitoring device attached to a subject, second physiological data of sympathetic nervous system activity in the subject. Using the at least one machine learning model and based on the baseline value of at least one physiological parameter, the method includes analyzing the second physiological data to predict an agitation episode of the subject and sending a signal to a second monitoring device to notify of the prediction of the agitation episode of the subject such that treatment can be provided to the subject to decrease sympathetic nervous system activity in the subject.

Abstract: A method of data collection of stool data via a mobile device operable to enable monitoring of gastrointestinal function. A related method of long-term monitoring of patient gastrointestinal function, using one or more signal processing tools (e.g. machine learning algorithms) for automatically interpreting patient stool data, including real-time patient-assessments, in order to detect an adverse clinical event from patient stool data. A system for facilitating real-time monitoring the gastrointestinal function, the system comprising: a camera on a mobile device, a user interface that facilitates self-monitoring of stool characteristics, so as to create health-monitoring data; mobile device storage, server storage, and remote storage (with at least one communication link between them) for storing some or all of the health-monitoring data; and a processor for interpreting such health-monitoring data for clinical or other health-monitoring application.